Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer

NCT04825990 is registered in ClinicalTrials.gov with Gruppo Oncologico del Nord-Ovest as lead sponsor.

NCT NCT04825990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04825990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 24, 2022
Completion date
October 27, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma